CARMELL CORP (CTCX) Stock Fundamental Analysis

NASDAQ:CTCX • US1429221039

0.1973 USD
+0 (+1.39%)
Last: Mar 7, 2025, 08:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

0

Overall CTCX gets a fundamental rating of 0 out of 10. We evaluated CTCX against 521 industry peers in the Biotechnology industry. CTCX may be in some trouble as it scores bad on both profitability and health. CTCX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year CTCX has reported negative net income.
  • CTCX had a negative operating cash flow in the past year.
CTCX Yearly Net Income VS EBIT VS OCF VS FCFCTCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

  • CTCX has a Return On Assets of -1047.34%. This is amonst the worse of the industry: CTCX underperforms 97.90% of its industry peers.
Industry RankSector Rank
ROA -1047.34%
ROE N/A
ROIC N/A
ROA(3y)-8.43%
ROA(5y)N/A
ROE(3y)-21.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTCX Yearly ROA, ROE, ROICCTCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -20 -40 -60

1.3 Margins

  • CTCX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTCX Yearly Profit, Operating, Gross MarginsCTCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • CTCX has more shares outstanding than it did 1 year ago.
  • CTCX has a worse debt/assets ratio than last year.
CTCX Yearly Shares OutstandingCTCX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M
CTCX Yearly Total Debt VS Total AssetsCTCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M

2.2 Solvency

  • CTCX has an Altman-Z score of -52.95. This is a bad value and indicates that CTCX is not financially healthy and even has some risk of bankruptcy.
  • CTCX has a Altman-Z score of -52.95. This is amonst the worse of the industry: CTCX underperforms 93.88% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -52.95
ROIC/WACCN/A
WACCN/A
CTCX Yearly LT Debt VS Equity VS FCFCTCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M

2.3 Liquidity

  • CTCX has a Current Ratio of 0.31. This is a bad value and indicates that CTCX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CTCX's Current ratio of 0.31 is on the low side compared to the rest of the industry. CTCX is outperformed by 94.41% of its industry peers.
  • CTCX has a Quick Ratio of 0.31. This is a bad value and indicates that CTCX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CTCX's Quick ratio of 0.29 is on the low side compared to the rest of the industry. CTCX is outperformed by 94.41% of its industry peers.
Industry RankSector Rank
Current Ratio 0.31
Quick Ratio 0.29
CTCX Yearly Current Assets VS Current LiabilitesCTCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for CTCX have decreased strongly by -335.78% in the last year.
  • Looking at the last year, CTCX shows a very negative growth in Revenue. The Revenue has decreased by -99.12% in the last year.
EPS 1Y (TTM)-335.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.39%
Revenue 1Y (TTM)-99.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.45%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CTCX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTCX Price Earnings VS Forward Price EarningsCTCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTCX Per share dataCTCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CTCX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CARMELL CORP

NASDAQ:CTCX (3/7/2025, 8:16:34 PM)

0.1973

+0 (+1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners8.88%
Inst Owner Change-0.22%
Ins Owners11.63%
Ins Owner Change0%
Market Cap5.94M
Revenue(TTM)32.80K
Net Income(TTM)-25.58M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 181.18
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.91
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS-0.13
TBVpS-0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1047.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-8.43%
ROA(5y)N/A
ROE(3y)-21.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.31
Quick Ratio 0.29
Altman-Z -52.95
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-335.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.39%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-99.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1727.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1727.38%
OCF growth 3YN/A
OCF growth 5YN/A

CARMELL CORP / CTCX FAQ

What is the ChartMill fundamental rating of CARMELL CORP (CTCX) stock?

ChartMill assigns a fundamental rating of 0 / 10 to CTCX.


What is the valuation status for CTCX stock?

ChartMill assigns a valuation rating of 0 / 10 to CARMELL CORP (CTCX). This can be considered as Overvalued.


How profitable is CARMELL CORP (CTCX) stock?

CARMELL CORP (CTCX) has a profitability rating of 0 / 10.


Can you provide the financial health for CTCX stock?

The financial health rating of CARMELL CORP (CTCX) is 0 / 10.